PH
|
≠ TT
|
TI
|
RN
|
RTT
|
NTT
|
NV
|
RN
|
---|
T2D
|
84
|
0.29
|
5th
|
7
|
77
|
0.92
|
5th
|
T1D
|
97
|
0.27
|
6th
|
2
|
95
|
0.98
|
2nd
|
RA
|
77
|
0.38
|
2nd
|
6
|
71
|
0.92
|
5th
|
HT
|
78
|
0.35
|
4th
|
5
|
73
|
0.94
|
4th
|
BD
|
59
|
0.27
|
6th
|
1
|
58
|
0.98
|
2nd
|
CD
|
135
|
0.36
|
3rd
|
0
|
135
|
1.00
|
1st
|
CAD
|
102
|
0.39
|
1st
|
4
|
98
|
0.96
|
3rd
|
- Abbreviations - PH - Phenotypes; ≠TT - Number of Therapeutic Targets; TI - Targetability Index; NTT - Novel Therapeutic Targets; RTT - Replicated Therapeutic Targets; NV - Novelty; RN - Rank; T2D - Type 2 Diabetes; BD - Bipolar Disorder; CD - Crohn's Disease; HT - Hypertension; T1D - Type 1 Diabetes; CAD - Coronary Artery Disease; RA - Rheumatoid Arthritis.
- Description of therapeutic targets and novel therapeutic targets. Total 452 unique therapeutic targets and total 428 unique novel therapeutic targets obtained for seven complex diseas